Table 2—

Effects of soy supplementation versus placebo on plasma hormone concentrations and creatinine

Soy
Placebo
Treatment difference (P value)
Baseline (n = 32)12 weeks (n = 32)% ChangeBaseline (n = 32)12 weeks (n = 32)% Change
LH (IU/l)28.4 ± 14.825.9 ± 12.6−4.28 ± 20.628.8 ± 14.528.3 ± 13.8+0.30 ± 21.80.866
FSH (IU/l)48.7 ± 18.744.6 ± 16.1−5.23 ± 16.849.2 ± 18.647.9 ± 18.3−2.29 ± 13.10.443
Catradiol (pmol/l)103.7 ± 51.2137.4 ± 60.4+42.7 ± 55.6117.6 ± 58.1140.0 ± 78.4+29.2 ± 76.80.079
Testosterone (nmol/L), n = 31*2.16 ± 0.851.77 ± 0.77−15.8 ± 32.82.19 ± 0.841.90 ± 0.97−11.4 ± 35.90.970
SHBG (nmol/l)39.3 ± 16.436.4 ± 14.7−4.98 ± 16.939.1 ± 17.136.0 ± 16.0−6.88 ± 14.90.985
Androstenedione (nmol/l)4.25 ± 2.253.97 ± 1.60+3.65 ± 36.34.73 ± 3.594.08 ± 1.88+8.31 ± 52.30.722
DHEAS (μmol/l)2.09 ± 1.172.01 ± 1.03−0.35 ± 21.32.02 ± 1.042.07 ± 1.28+0.40 ± 22.50.889
Creatinine (μmol/l)77.6 ± 15.875.3 ± 15.9−2.53 ± 9.4576.2 ± 16.178.2 ± 18.6+2.95 ± 11.70.072
TSH (mU/l)2.15 ± 1.082.27 ± 1.35+9.32 ± 36.42.18 ± 1.082.26 ± 1.18+9.48 ± 46.10.739
Free thyroxine (pmol/l)14.1 ± 1.5313.7 ± 1.65−2.50 ± 8.4713.8 ± 1.7514.4 ± 1.87+4.26 ± 9.220.004
Free triiodothyronine (pmol/l)3.18 ± 0.463.23 ± 0.50+2.55 ± 15.33.26 ± 0.633.29 ± 0.58+3.69 ± 25.70.970
  • Data are means ± SD. P value was calculated using Wilcoxon’s signed-rank test.

  • *

    * One patient was removed because the testosterone result was an extreme outlier (>3 SD from the mean of the group). % Change, percent difference compared with baseline; LH, luteinizing hormone, FSH, follicle-stimulating hormone; SHBG, sex hormone binding globulin; DHEAS, dehydroepiandrosterone sulfate; TSH, thyroid-stimulating hormone.